Evogene Ltd EVGN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Evogene and Tel Aviv University's Blavatnik Center for Drug Discovery Announce Joint Initiative to Accelerate AI-Driven Small-Molecule Drug Discovery
-
Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica
-
Evogene to Present at the 24th Schrödinger European User Group Meeting
-
Evogene Schedules First Quarter 2026 Financial Results Release
Trading Information
- Previous Close Price
- $0.58
- Day Range
- $0.57–0.68
- 52-Week Range
- $0.37–1.50
- Bid/Ask
- $0.62 / $0.67
- Shares Outstanding
- 12.10M
- Market Cap
- $7.61M
- Volume/Avg
- 11,318 / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.94
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the industrial segment, followed by Agriculture.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 52
- Website
- https://www.evogene.com
Valuation
|
Metric
|
EVGN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 2.94 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
EVGN
|
|---|---|
Quick Ratio | 2.75 |
Current Ratio | 2.79 |
Interest Coverage | −3.87 |
Quick Ratio
EVGN
Profitability
|
Metric
|
EVGN
|
|---|---|
Return on Assets (Normalized) | −55.03% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −62.30% |
Return on Assets
EVGN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|#<vsHY | LOCK|T#!KX | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|&C>^yP% | LOCK|w@T< | $71B | |||
| argenx SE ADR
ARGX
| LOCK|g%J?>Zq | LOCK|L!! | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|L&C&#k | LOCK|%Z | $36B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|$W%&zd | LOCK|<@%#v | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|khp#gn^^ | LOCK|V#%h | $26B | |||
| Moderna Inc
MRNA
| LOCK|JpJDx#n | LOCK|#%s | $25B | |||
| Incyte Corp
INCY
| LOCK|$LP&&jR | LOCK|T?k | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|Kdk<Sx? | LOCK|GV | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|r&JS?! | LOCK|L% | $16B |
United States